文献速递银屑病与炎症性皮肤病

HLA-Cw6与银屑病

HLA-Cw6 and psoriasis.
PubMed 文献 · Br J Dermatol · 2018-03-02

本文综述HLA-Cw6等位基因与银屑病的关系。HLA-Cw6是银屑病最强关联易感位点之一,全球频率白人高于亚洲人,与I型早发型银屑病相关。该等位基因影响疾病进程、表型、严重度、共病及治疗反应,携带者对甲氨蝶呤和乌司奴单抗反应更佳。

要点

  • HLA-Cw6与I型早发型银屑病相关,白人频率高于亚洲人。
  • 携带者更常见点滴状银屑病、Koebner现象及四肢躯干受累。
  • 携带者对甲氨蝶呤和乌司奴单抗反应更佳。

核心结论

  • HLA-Cw6是银屑病最强关联易感等位基因之一,影响疾病进程、表型、严重度、共病及治疗结局。
  • 鉴于银屑病发病机制多样及HLA-Cw6阳性率在不同种族间差异大,需更多研究确认其作用。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • HLA-Cw6全球频率差异大,白人 generally 高于亚洲人。
  • HLA-Cw6与I型早发型银屑病相关。
  • HLA-Cw6阳性患者常见压力、肥胖和链球菌性咽炎。
  • HLA-Cw6与点滴状银屑病相关,携带者更易有臂、腿和躯干受累及Koebner现象。
  • 银屑病关节炎伴HLA-Cw6者更常早发,且皮肤症状常先于肌肉骨骼症状。

关键数值与推荐

  • 多项研究显示HLA-Cw6阳性患者对甲氨蝶呤和乌司奴单抗更敏感。
  • 在一项关键III期研究的事后分析中,乌司奴单抗疗效差异仅为中等。
  • HLA-Cw6阳性在常规治疗失败的高需求患者中 tends to be less frequent。

临床怎么用

  • HLA-Cw6状态可能辅助预测银屑病早发、点滴状表型及甲氨蝶呤或乌司奴单抗反应。
  • 临床可关注HLA-Cw6阳性患者的压力、肥胖及链球菌咽炎等诱因。

局限性

  • 摘要未报告检索策略及纳入研究数量。
  • HLA-Cw6在不同种族间阳性率差异大,需更多研究确认其作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis is a multifactorial disease with a strong genetic background. HLA-Cw6 is one of the most strongly associated psoriasis susceptibility alleles. It is repeatedly observed to affect disease course, phenotypic features, severity, comorbidities and treatment outcomes. To the best of our knowledge, the roles of HLA-Cw6 in psoriasis have not yet been thoroughly reviewed. The worldwide frequency of the HLA-Cw6 allele varies greatly, with it being generally higher in white people than in Asians. The allele is associated with type I early-onset psoriasis. Stress, obesity and streptococcal pharyngitis are commonly observed in HLA-Cw6-positive patients. Phenotypically, HLA-Cw6 has been found to be associated with guttate psoriasis. In addition, patients carrying the allele are more likely to have arm, leg and trunk involvement, and the Koebner phenomenon. Patients with psoriatic arthritis with HLA-Cw6 more often have early onset and tend to show cutaneous symptoms before musculoskeletal symptoms. HLA-Cw6-positive patients have been shown in several studies to be more responsive to methotrexate and ustekinumab. However, this difference in ustekinumab efficacy was only moderate in a post-hoc analysis of a pivotal phase III study. HLA-Cw6 positivity also tends to be less frequent in high-need patients who fail conventional therapy. Small studies have also investigated the role of HLA-Cw6 in remission of psoriasis during pregnancy, and with the comorbidities of photosensitivity and atherosclerosis. Given the diverse nature of psoriasis pathogenesis, as well as the difference of HLA-Cw6 positivity in different ethnic groups, more studies are needed to confirm the role of HLA-Cw6 in psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018. PMID: 29072309. doi:10.1111/bjd.16083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。